TickerGuard
Buy Day today: Poor (44) Weak market breadth · no major macro event
CUE

Cue Biopharma

Healthcare · Biotechnology

17.50$ -6.2% vs. previous close Closing price · As of: Nov 12, 2026

Ownership

Ownership Structure

Who owns Cue Biopharma (CUE)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 87.6% of the shares are freely tradable; institutional investors hold 14.9%.

Institutional ownership ?Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings. 14.9%
Insiders ?Share of the stock held by the executives, founders and major shareholders of the company itself. 18.6%
Float ?Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders. 87.6%
Short % of float ?Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices. 11.5%
Shares Outstanding ?Total number of shares issued. Price times share count gives market cap. 7Mio.

Largest Shareholders

Institutions

Institutions CUE
Name Stake (%) Shares Change (%) Date
Bleichroeder LP 5.10 370,682 +63.1 06/30/2026
Driehaus Capital Management LLC 4.02 292,144 +0.0 06/30/2026
Vanguard Capital Management, LLC 2.23 161,700 +97.4 06/30/2026
Ikarian Capital, LLC 1.44 104,364 +0.0 06/30/2026
Polygon Management Ltd 1.29 93,819 +0.0 06/30/2026
StemPoint Capital LP 0.92 66,995 +0.0 06/30/2026
BlackRock Inc 0.80 57,807 +286.1 06/30/2026
ADAR1 Capital Management LLC 0.76 55,193 +0.0 06/30/2026
Lion Point Capital, LP 0.73 52,928 -27.9 06/30/2026

Funds

Funds CUE
Name Stake (%) Shares Change (%) Date
Vanguard MStar Total Stk Mkt Idx Invest 3.21 232,984 +108.3 09/30/2026

Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.

Insider holdings

Insider holdings CUE
Person Role Shares Value As of Type
Lin Shao-Lee Chief Executive Officer 694,908 12,160,890 $ Oct 12, 2026 direct
Ray Sumita Chief Legal Compliance Officer 116,701 2,042,268 $ Oct 12, 2026 direct
Meluzio Michael Vincent VP, Prin. Accounting Officer 47,817 836,798 $ Oct 12, 2026 direct

Holdings as of each person's most recent SEC Form 4 filing — excluding options and RSUs, which are not shares yet. Holdings may have changed between two filings.

Insiders

Insider Transactions

Insider Transactions
Date Person Role Type Shares Price Value
Oct 12, 2026 Meluzio Michael Vincent VP, Prin. Accounting Officer Sell 1,144 28.05 32,089
Oct 12, 2026 Lin Shao-Lee Chief Executive Officer Sell 1,087 28.05 30,490
Oct 12, 2026 Lin Shao-Lee Chief Executive Officer Sell 10,000 27.50 275,000
Oct 12, 2026 Ray Sumita Chief Legal Compliance Officer Sell 1,844 28.05 51,724
Aug 13, 2026 Meluzio Michael Vincent VP, Prin. Accounting Officer Sell 3 31.13 93
Aug 13, 2026 Meluzio Michael Vincent VP, Prin. Accounting Officer Sell 4,106 30.35 124,617
Aug 13, 2026 Meluzio Michael Vincent VP, Prin. Accounting Officer Sell 1,519 29.37 44,613
Aug 13, 2026 Meluzio Michael Vincent VP, Prin. Accounting Officer Other 13,647 0.00 –
Aug 13, 2026 Ray Sumita Chief Legal Compliance Officer Sell 4 31.13 125
Aug 13, 2026 Ray Sumita Chief Legal Compliance Officer Sell 6,442 30.35 195,515
Aug 13, 2026 Ray Sumita Chief Legal Compliance Officer Sell 2,383 29.37 69,989
Aug 13, 2026 Ray Sumita Chief Legal Compliance Officer Other 18,196 0.00 –
Aug 13, 2026 Lin Shao-Lee Chief Executive Officer Sell 10,460 29.48 308,361
Aug 13, 2026 Lin Shao-Lee Chief Executive Officer Sell 2,375 28.11 66,761
Aug 13, 2026 Lin Shao-Lee Chief Executive Officer Sell 5,423 27.19 147,451
Aug 12, 2026 Lin Shao-Lee Chief Executive Officer Sell 5,775 27.75 160,256
Aug 12, 2026 Lin Shao-Lee Chief Executive Officer Sell 34,225 26.99 923,733
Aug 12, 2026 Lin Shao-Lee Chief Executive Officer Other 109,179 0.00 –

Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character. View all insider transactions →

Data as of: November 12, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?